Video Series

Experts explore HER2 mutations and the critical role of comprehensive molecular profiling in optimizing treatment for non-small cell lung cancer patients.

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient outcomes.

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with longer PFS, suggesting T-cell composition may serve as a biomarker to guide patient selection.

Michael Wang, MD, reviews ASH 2025 data showing durable safety with long-term BTK inhibition, promising next-generation targeted agents, sustained CAR T-cell efficacy, and evidence favoring upfront combination therapy over sequential treatment in mantle cell lymphoma.

While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with operational efficiency and cost savings serving as added benefits rather than decision drivers.

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T feasibility, expansion, and durability compared with later-line treatment.

Explore the evolution of IgA nephropathy treatment, highlighting new guidelines and targeted therapies that improve patient outcomes.

Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency and generate cost savings for oncology practices without affecting efficacy or safety.

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK inhibitor–refractory disease.

Managed care organization and providers should conduct early formulary reviews and education to ensure rapid access to dextromethorphan-bupropion upon approval, potentially delaying facility placement for patients with Alzheimer disease.

Managed care organizations should evolve cost models to capture savings from dextromethorphan-bupropion’s safety profile, which avoids costly complications associated with traditional Alzheimer disease agitation therapies.

Recent trials highlight T-DXd's superior efficacy and manageable toxicity in treating high-risk HER2-positive breast cancer, reshaping treatment strategies.

Explore the transformative potential of bispecific antibodies in multiple myeloma, offering hope for improved patient outcomes and possible cures.

Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, emphasizing equity and education.

Panelists discuss how integrating xanomeline/trospium into clinical practice may expand safe and effective treatment options.

Shared decision-making—balancing clinical data with the patient's personal, logistical, and risk-tolerance factors—is essential for managing a chronic condition like follicular lymphoma.

Panelists discuss how the muscarinic pathway of xanomeline/trospium offers a safer, nondopaminergic approach to schizophrenia care.

Panelists discuss how balancing adverse-effect management with adherence optimization drives effective therapy transitions.

Panelists discuss how thoughtful sequencing of antipsychotics enhances adherence, safety, and long-term efficacy.

Discussion of patient selection criteria, logistical challenges, toxicity management, and when to favor each immunotherapy approach.

Examination of how combination therapy and next-generation immunotherapies are poised to redefine RRMM treatment over the next 5 years.

Experts discuss the unmet needs in desmoid tumor management, emphasizing personalized treatment, quality of life, and the importance of specialized care.

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma.

Explore the latest advancements in HER2-positive breast cancer treatments, highlighting the promising results of DESTINY-Breast trials for improved patient outcomes.

Experts discuss the challenges of diagnosing rare diseases and the potential role of AI in improving patient management and treatment outcomes.

Achieving equitable access to anti-fibrotic drugs requires multi-stakeholder collaboration, while the most critical unmet clinical need remains overcoming late and misdiagnosis through targeted education to ensure earlier therapy and better patient outcomes.

Explore the integration of Desmoid Tumor Working Group recommendations with NCCN guidelines and the importance of shared decision-making in patient care.

Following the clinical success of new agents like nerandomilast, the next critical steps for managing ILD involve dismantling financial and geographical barriers to access, and rigorously integrating comprehensive, multidisciplinary supportive care including pulmonary rehabilitation and comorbidity management.